August 2012
-
Following Pulmatrix’s recent successful public offering, Pulmatrix and Cipla subsidiary Cipla Technologies (Cip Tec) have entered into a definitive agreement in which Cipla will acquire rights to the Pulmazole itraconazole DPI for the treatment of… Read more . . .
-
Cipla Limited has announced the launch of its Niveoli extra-fine particle beclomethasone/formoterol fumarate MDI for the treatment of asthma and COPD in adults in India. Cipla India Business Head Nikhil Chopra commented, “Cipla is pleased… Read more . . .
-
Insmed Incorporated said that the U.S. Patent and Trademark Office (USPTO) has issued US patent No. 10,251,900, titled “Methods for treating pulmonary non-tuberculous mycobacterial infections,” which is the 10th US patent covering the use of… Read more . . .
-
According to Synspira Therapeutics, the company’s SNSP113 inhaled glycopolymer for the treatment of cystic fibrosis has received orphan drug desination from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP). The FDA granted… Read more . . .
-
Noveome Biotherapeutics said that it has closed a $15 million Series D financing round that will help to fund further development of its ST266 biologic. Intranasal formulations of ST266 are in development for the treatment… Read more . . .
-
Otitopic, which recently announced that it received a new patent for the us of inhaled aspirin for the treatment of myocardial infarction, now says that it also plans to develop its Asprihale aspirin DPI for… Read more . . .
-
Pulmatrix said that it has closed a public offering with expected gross proceeds of $16.6 million that will be used primarily for development of its inhaled therapies, especially Pulmazole inhaled itraconazole for the treatment of… Read more . . .
-
The UK’s National Institute for Health Care and Excellence (NICE) has issued a new “patient decision aid” that emphasizes that a metered dose inhaler “contains propellant, so it has a higher carbon footprint than a… Read more . . .
-
Endo International has announced that its subsidiary Endo Procurement Operations Limited recently reached an agreement with Merck to distribute an authorized generic of Proventil HFA albuterol sulfate MDI in the US. Endo operating company Par… Read more . . .
-
According to Evoke Pharma, the FDA has issued a complete response letter in response to the company’s NDA for Gimoti metoclopramide nasal spray for the treatment of diabetic gastroparesis. The PDUFA date for completion of… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.